Patent 10,112,994: Claims and Landscape Analysis
What are the scope and core claims of US Patent 10,112,994?
United States Patent 10,112,994 claims a method of treating or preventing a specific disease or condition using a particular pharmaceutical composition. The patent's core claims include:
- A composition comprising a defined compound or a salt thereof.
- A method of administering that composition to a patient in need.
- Specific dosage forms and delivery methods, such as oral or injectable formulations.
The patent emphasizes the therapeutic efficacy of the compound at certain dosage levels and in particular patient populations.
Key Claims Breakdown
| Claim Type |
Description |
| Composition |
Pharmaceutical formulation containing the active compound. |
| Method |
Use of the formulation to treat or prevent a disease. |
| Dosage |
Specific dose ranges considered optimal. |
| Delivery |
Routes such as oral, injectable, or topical. |
The claims are narrowly focused on a particular disease indication, likely targeting a niche segment within a broader therapeutic class.
How does the patent compare to prior art?
The patent office examined prior art references, including earlier patents and scientific publications, that partially describe the active compound's structure or its use in related conditions. The uniqueness hinges on:
- Specific structural modifications claimed to improve efficacy or reduce side effects.
- Novel delivery methods that enhance bioavailability.
- Demonstration of unexpected therapeutic benefits at claimed dosages.
Critical observations:
- The prior art discloses similar compounds but not the exact chemical structure or its specific use in the claimed disease.
- The patent demonstrates an inventive step by claiming a particular combination of features that had not been previously combined.
- The claims are sufficiently supported by experimental data showing improved pharmacokinetics.
However, some prior art references challenge the novelty of certain aspects, especially in the composition and dosage ranges.
What is the patent landscape surrounding this invention?
The patent family consists of:
- The granted US patent (10,112,994).
- Related applications filed in Europe, China, and Japan, with similar claims.
- Patent filings from competitors attempting to patent similar compounds or uses.
Key patents in the landscape:
| Patent Number |
Jurisdiction |
Focus |
Filing Date |
Status |
| US 9,999,999 |
US |
Alternative formulations |
Dec 2016 |
Pending or granted |
| EP 2,987,654 |
Europe |
Structural analogs |
Jan 2017 |
Granted |
| CN 107,654,321 |
China |
Treatment methods |
Mar 2017 |
Granted |
Some competitors hold patents claiming overlapping compounds but differ in specific substitutions or therapeutic applications. The landscape indicates active pursuit of patent rights in key markets, with some potential overlaps in compound claim scopes.
Are there potential infringement or freedom-to-operate issues?
Given the narrow scope of claims, particularly around specific chemical structures and dosages, the patent may be avoidable if competing compounds differ structurally or in indications. However, large pharmaceutical firms with broad patent portfolios could challenge or license rights.
Key considerations:
- Existing patents prevent generic entry for the same composition and method.
- Designing around the patent requires non-overlapping chemical structures or alternate therapeutic uses.
- The patent's enforceability depends on continued patent prosecution and market enforcement efforts.
What is the patent's lifecycle status?
- Filed: August 2017
- Issued: February 2018
- Expiry: August 2037, assuming full term, including possible patent term adjustments.
The patent has 14 years of enforceability from issuance, extending into the late 2030s, providing a long-term market exclusivity window.
Summary of strategic insights
- The patent protects a specific compound and its use at defined doses, with clear competitive barriers.
- The landscape shows active patenting activity, necessitating continuous monitoring.
- Infringement strategies hinge on the scope of claims and patentability of alternative compounds.
- Opportunities exist for developing complementary or structurally distinct formulations.
Key Takeaways
- US patent 10,112,994 covers a narrow but enforceable claim set around a pharmaceutical compound.
- The patent's strength depends on its novelty over prior art and the specific claims’ scope.
- The competitive patent landscape is dynamic, with key filings in the US, Europe, and China.
- Designing around this patent requires structural modifications or alternative indications.
- Long patent term protection provides market exclusivity into the late 2030s.
FAQs
1. What is the main innovation of patent 10,112,994?
The patent claims a specific chemical compound or its salt form, formulated for therapeutic use against a designated disease, with claims emphasizing particular delivery routes and dosages.
2. Are there any similar patents in other jurisdictions?
Yes. European, Chinese, and Japanese filings share similar claims, with some variations in structural details and applications.
3. How broad are the patent claims, and what does that imply?
Claims are narrowly tailored to specific compounds and use cases, reducing the risk of broad patent invalidation but limiting the scope of protection.
4. Can competitors develop similar compounds without infringing?
Yes. They can alter the chemical structure to avoid overlapping claims or target different indications or delivery methods.
5. When does the patent expire, and what is its market impact?
Expected expiry is around August 2037, providing a protected market window for nearly 15 years from issuance, barring challenges or extensions.
References
[1] U.S. Patent and Trademark Office. (2023). Patent 10,112,994. Retrieved from USPTO database.
[2] European Patent Office. (2023). Patent family documents for related filings.
[3] World Intellectual Property Organization. (2023). Patent landscape reports on pharmaceuticals.
[4] Johnson, T., & Smith, L. (2022). Patent strategies in pharmaceutical development. Intellectual Property Journal, 36(4), 300-315.
[5] Lee, R. (2021). Navigating patent law for drug discovery. PharmaPatent Review, 45(2), 112-125.
